1E8Y | A:525-725 | STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN, LY294002, QUERCETIN, MYRICETIN AND STAUROSPORINE |
1E8Z | A:525-725 | STRUCTURE DETERMINANTS OF PHOSPHOINOSITIDE 3-KINASE INHIBITION BY WORTMANNIN, LY294002, QUERCETIN, MYRICETIN AND STAUROSPORINE |
1HE8 | A:523-725 | RAS G12V - PI 3-KINASE GAMMA COMPLEX |
2A4Z | A:524-725 | CRYSTAL STRUCTURE OF HUMAN PI3KGAMMA COMPLEXED WITH AS604850 |
2A5U | A:525-725 | CRYSTAL STRUCTURE OF HUMAN PI3KGAMMA COMPLEXED WITH AS605240 |
2CHW | A:525-725 | A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110 ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-39 |
2CHX | A:525-725 | A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-90 |
2CHZ | A:525-725 | A PHARMACOLOGICAL MAP OF THE PI3-K FAMILY DEFINES A ROLE FOR P110ALPHA IN SIGNALING: THE STRUCTURE OF COMPLEX OF PHOSPHOINOSITIDE 3-KINASE GAMMA WITH INHIBITOR PIK-93 |
2RD0 | A:482-695 | STRUCTURE OF A HUMAN P110ALPHA/P85ALPHA COMPLEX |
2V4L | A:525-725 | COMPLEX OF HUMAN PHOSPHOINOSITIDE 3-KINASE CATALYTIC SUBUNIT GAMMA (P110 GAMMA) WITH PIK-284 |
3CSF | A:525-725 | CRYSTAL STRUCTURE OF PI3K P110GAMMA CATALYTICAL DOMAIN IN COMPLEX WITH ORGANORUTHENIUM INHIBITOR DW2 |
3CST | A:525-725 | CRYSTAL STRUCTURE OF PI3K P110GAMMA CATALYTICAL DOMAIN IN COMPLEX WITH ORGANORUTHENIUM INHIBITOR E5E2 |
3DBS | A:525-725 | STRUCTURE OF PI3K GAMMA IN COMPLEX WITH GDC0941 |
3DPD | A:525-725 | ACHIEVING MULTI-ISOFORM PI3K INHIBITION IN A SERIES OF SUBSTITUTED 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINES |
3ENE | A:525-725 | COMPLEX OF PI3K GAMMA WITH AN INHIBITOR |
3IBE | A:526-725 | CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR BOUND TO PI3 KINASE GAMMA |
3L13 | A:525-725 | CRYSTAL STRUCTURES OF PAN-PI3-KINASE AND DUAL PAN-PI3-KINASE/MTOR INHIBITORS |
3L16 | A:525-725 | DISCOVERY OF (THIENOPYRIMIDIN-2-YL)AMINOPYRIMIDINES AS POTENT, SELECTIVE, AND ORALLY AVAILABLE PAN-PI3-KINASE AND DUAL PAN-PI3-KINASE/MTOR INHIBITORS FOR THE TREATMENT OF CANCER |
3L17 | A:525-725 | DISCOVERY OF (THIENOPYRIMIDIN-2-YL)AMINOPYRIMIDINES AS POTENT, SELECTIVE, AND ORALLY AVAILABLE PAN-PI3-KINASE AND DUAL PAN-PI3-KINASE/MTOR INHIBITORS FOR THE TREATMENT OF CANCER |